Alpelisib and Fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the German PRAEGNANT trial
在德国PRAEGNANT试验中,Alpelisib和Fulvestrant被用于治疗PIK3CA突变、激素受体阳性、HER2阴性的晚期乳腺癌。
期刊:Breast Cancer Research and Treatment
影响因子:3
doi:10.1007/s10549-026-07939-z
Hörner, Manuel; Tretschock, Lara M; John, Nelson; Ziegler, Philipp; Häberle, Lothar; Uhrig, Sabrina; Goossens, Chloë; Amann, Niklas; Cieslik, Jan-Philipp; Dannehl, Dominik; Deutsch, Thomas M; Dimpfl, Moritz; Ehlert, Max; Eichstädt, Kathleen; Englisch, Alexander; Köpke, Melitta B; Krückel, Annika; Link, Theresa; Müller, Annika; Reinhardt, Kristin; Roth, Jonas; Schäffler, Henning; Sych, Lea; Tegeler, Christian M; Wichmann, Catharina; Banys-Paluchowski, Maggie; Princk, Henriette; Rody, Achim; Brucker, Sara Y; Ditsch, Nina; Ettl, Johannes; Fehm, Tanja; Hack, Carolin C; Hadji, Peyman; Hein, Alexander; Janni, Wolfgang W; Kolberg, Hans-Christian; Lüftner, Diana; Lux, Michael P; Müller, Volkmar; Schneeweiss, Andreas; Taran, Florin-Andrei; Tesch, Hans; Wallwiener, Diethelm; Marmé, Frederik; Seitz, Stephan; Belleville, Erik; Hartkopf, Andreas; Michel, Laura L; Wallwiener, Markus; Fasching, Peter A; Tauber, Nikolas